1. Home
  2. JYD vs SNTI Comparison

JYD vs SNTI Comparison

Compare JYD & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jayud Global Logistics Limited

JYD

Jayud Global Logistics Limited

N/A

Current Price

$1.65

Market Cap

11.5M

ML Signal

N/A

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

N/A

Current Price

$0.18

Market Cap

10.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JYD
SNTI
Founded
2001
2016
Country
China
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
10.4M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
JYD
SNTI
Price
$1.65
$0.18
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $13.50
AVG Volume (30 Days)
★ 1.9M
1.2M
Earning Date
11-17-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 77.31
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$127.27
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.47
$0.15
52 Week High
$5.75
$57.60

Technical Indicators

Market Signals
Indicator
JYD
SNTI
Relative Strength Index (RSI) 61.62 14.40
Support Level $0.65 N/A
Resistance Level $2.12 $7.00
Average True Range (ATR) 0.23 0.03
MACD 0.01 0.05
Stochastic Oscillator 51.69 27.58

Price Performance

Historical Comparison
JYD
SNTI

About JYD Jayud Global Logistics Limited

Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, fragmented logistics, and chartered airline freight services, supply chain management, and other value-added services.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: